Process tank for sterile production

You can find this article in the article group: Filtration tank, Process tanks, Process vessels, Sterile tank, Stirring tank
BiotechnologyChemical industryPharmaceutical

Item description:

Pharmaceutical process tank for the sterile production of serum pursuant to PED 2014/68/EU cat. 4/module G, ATEX Directive 2014/34/EU and MD 2006/42/EU.
Top section as pressure dome cover with welded conical nozzle. Torispherical base design. The tank is equipped with a control system, analysis technology and filter. The tank is equipped with a heating/cooling jacket and insulation cover.
Equipment also includes:
  • Magnetic stirrer for a viscosity of 250 mPas
  • Filter for sterile filtration
  • pH measurement
  • O² measurement
  • Metaglas sight glass
  • LED sight glass lights
  • D-ended sight glass in casing
  • Rupture disc / safety valve
  • Product tubes
  • CIP-compatible sampling and outlet valve
  • CIP cleaning nozzle
  • ATEX design
  • Control cabinet in line with ATEX
Industry: Pharmaceutical
Cytostatic drugs, serum production
10l – 800l
Tank product chamber:
p = -0,5 / +3,5 bar,
t = -10 / +150 °C
Double wall:
p = -0,5 / +4,5 bar,
t = -10 / +150 °C
Parts in contact with product 1.4539 , Delta ferrite <1%, with APZ 3.2/3.1 AD 2000, Ra <0.8µm

Dear Sir or Madam,
Dear Mr Weinert,

On April 30, 2021, we will open another site at Allergopharma GmbH & Co. KG in Reinbek to support COVID 19 vaccine production in the presence of Federal Minister Spahn and Minister President Günther. We would have been pleased to invite you to this opening.

Unfortunately, this was not possible due to the pandemic.
We would therefore like to take this opportunity to thank you for your extraordinary commitment to supplying equipment at short notice to support vaccine production. Allergopharma, as part of Dermapharm Holding SE, is now a further partner in the Europe-wide production network for the vaccine of BioNTech and Pfizer. This network now comprises more than a dozen important pharmaceutical manufacturers and suppliers. From now on, one of four production steps will take place in Reinbek: the vaccine formulation. This is where our mRNA active ingredient is combined with the lipids. A protective shell is created around the mRNA and the vaccine can reach its target in the body to induce the necessary immune response.

Your company has made a very important contribution to the global pandemic response with great know-how and under incredible time pressure. We would like to express our sincere thanks to you and your team! Without their commitment, the successful completion of the project would not have been possible.
We look forward to working with you in partnership in the future!

Dr. Hans-Georg Feldmeier – CEO Dermapharm SE
Dr. Sierk Poetting – CFO and COO BioNTech SE